Washington University School of Medicine: Communicable Diseases trials

The registry lists 13 Communicable Diseases studies with Washington University School of Medicine as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 1Phase 2 2Phase 3 2Phase 4 4No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 InfectionTerminatedNCT04341727Phase 3Results posted
• Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant RecipientsCompletedNCT02351180Phase 1/2Results posted
• Autologous Fecal TherapyCompletedNCT02046525Phase 2Results posted
• Probiotics to Promote Intestinal HealthCompletedNCT02046512Phase 4Results posted
• Individualized vs. Household MRSA DecolonizationCompletedNCT01814371Not applicableResults posted
• The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant BacteriaCompletedNCT01551186Phase 4Results posted
• Staphylococcus Aureus Decolonization StudyCompletedNCT00731783Not applicableResults posted
• Reducing Catheter-Related Bloodstream Infections in the ICU With a Chlorhexidine-Impregnated Sponge (BIOPATCH)CompletedNCT00548132Phase 4Results posted
• The Natural History of Community-Associated MRSA Infections and Decolonization StrategiesCompletedNCT00513799Not applicableResults posted
• Effect of Pea Fiber Supplementation on the Gut Microbiota and Host Metabolome and Proteome (FIB)CompletedNCT04159259Not applicable
• Controlled Clinical Trial of Supplemental Oxygen for the Prevention of Post-Cesarean Infectious MorbidityCompletedNCT00603603Not applicable
• Trial Evaluating the Efficacy of a Chlorhexidine-Impregnated Sponge (BIOPATCH®) to Reduce Catheter-Related Bloodstream Infections in Hemodialysis PatientsCompletedNCT00550693Phase 4
• Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell TransplantTerminatedNCT00241345Phase 3